<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105208</url>
  </required_header>
  <id_info>
    <org_study_id>15188</org_study_id>
    <secondary_id>Biocef-S</secondary_id>
    <nct_id>NCT01105208</nct_id>
  </id_info>
  <brief_title>Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension</brief_title>
  <official_title>Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef From Bayer (Cephalexin Suspension 250 mg/5 mL and Equivalent Concentration of Keflex Pediatrico From Eli Lilly (Cephalexin Suspension 125 mg/5mL) in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Corporación Bonima S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose, two treatments (two cephalexin suspension brands), two sequences, cross-over
      design was used with a washout of 7 days between the two study periods. Treatment groups
      balanced with the same number of healthy volunteers who were randomly (in two strata: male
      and female) assigned to the study drug administration sequences
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least square estimator of average maximum plasmatic concentration (log transformed)</measure>
    <time_frame>After two months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Least square estimator of area under the pharmacokinetic curve (log transformed)</measure>
    <time_frame>After two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum concentration is reached</measure>
    <time_frame>After two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the pharmacokinetic curve from time=0 to last blood sample</measure>
    <time_frame>After two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance constant of plasmatic concentrations of study drug</measure>
    <time_frame>After two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life of plasmatic concentration of study drug</measure>
    <time_frame>After two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Anti-Infective Agents</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin suspension (Optocef, BAYO5448 )</intervention_name>
    <description>Single dose of 500 mg / 10 mL</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin suspension (Keflex)</intervention_name>
    <description>Single dose of 500 mg / 20 mL</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female volunteers age between 18 and 55 years old with normal vital
             signs, electrocardiogram (ECG), blood chemistry, liver function profile and urinalysis

        Exclusion Criteria:

          -  History of illnesses or any organic abnormalities that could affect the results of the
             study

          -  History of abuse tobacco or alcohol or regular use of recreational or therapeutic
             drugs

          -  Subjects that have taken any medication within 14 days or that are in an elimination
             period of less than 7 half-lives (whichever is longest) before study startup.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Morelia</city>
        <state>Michoacán</state>
        <zip>58256</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

